{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:13:29Z","timestamp":1794665609848,"version":"4.9.1"},"reference-count":73,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.beha.2023.101466","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T02:33:19Z","timestamp":1680748399000},"page":"101466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Allogeneic hematopoietic cell transplantation in acute myeloid leukemia"],"prefix":"10.1016","volume":"36","author":[{"given":"Gray","family":"Magee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-0698","authenticated-orcid":false,"given":"Brittany Knick","family":"Ragon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.beha.2023.101466_bib1","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.beha.2023.101466_bib2","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2023.101466_bib3","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.beha.2023.101466_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","article-title":"Hematopoietic stem cell transplantation for patients with AML in first complete remission","volume":"127","author":"Cornelissen","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2023.101466_bib5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2023.101466_bib6","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.beha.2023.101466_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.beha.2023.101466_bib8","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.beha.2023.101466_bib9","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101466_bib10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MOH.0b013e32834ba94c","article-title":"Allogeneic stem cell transplantation in first complete remission","volume":"18","author":"Oran","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"12","key":"10.1016\/j.beha.2023.101466_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2023.101466_bib12","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial","volume":"118","author":"Burnett","year":"2002","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2023.101466_bib13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC\/GIMEMAAML-10 trial","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101466_bib14","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101466_bib15","first-page":"1874","article-title":"Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study","volume":"10","author":"Reiffers","year":"1996","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2023.101466_bib16","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/cncr.20945","article-title":"Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission","volume":"103","author":"Yanada","year":"2005","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.beha.2023.101466_bib17","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.beha.2023.101466_bib18","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.beha.2023.101466_bib19","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1158\/1078-0432.CCR-22-0809","article-title":"Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: an ALWP\/EBMT analysis","volume":"28","author":"Nagler","year":"2022","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101466_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2022-159962","volume":"140","author":"Stelljes","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2023.101466_bib21","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2023.101466_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101466_bib23","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101466_bib24","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.V92.4.1455","article-title":"Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia","volume":"92","author":"Clift","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101466_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.beha.2023.101466_bib26","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101466_bib27","first-page":"359","article-title":"Influencing factors of cardiorespiratory fitness in allogeneic stem cell transplant candidates prior to transplantation","volume":"29","author":"Limbach","year":"2021","journal-title":"Support Care Cancer : Off J Multinatl Assoc Support Care Cancer"},{"issue":"25","key":"10.1016\/j.beha.2023.101466_bib28","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1056\/NEJMoa011826","article-title":"Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation","volume":"345","author":"Petersdorf","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.beha.2023.101466_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM198901263200401","article-title":"Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma","volume":"320","author":"Anasetti","year":"1989","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101466_bib30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2014.09.017","article-title":"Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)","volume":"21","author":"Howard","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101466_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.beha.2023.101466_bib32","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2023.101466_bib33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/bmt.2013.50","article-title":"Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS","volume":"48","author":"Robin","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"36","key":"10.1016\/j.beha.2023.101466_bib34","doi-asserted-by":"crossref","first-page":"5695","DOI":"10.1200\/JCO.2006.08.0952","volume":"24","author":"Yakoub-Agha","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2023.101466_bib35","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2004-03-0803","article-title":"Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome","volume":"104","author":"Flomenberg","year":"2004","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2023.101466_bib36","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood.2022015860","article-title":"HLA-DQ heterodimers in hematopoietic cell transplantation","volume":"139","author":"Petersdorf","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2023.101466_bib37","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood-2003-02-0430","article-title":"Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000)","volume":"102","author":"Kanda","year":"2003","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.beha.2023.101466_bib38","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.beha.2023.101466_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/imm.12921","article-title":"Natural killer cell cytotoxicity and its regulation by inhibitory receptors","volume":"154","author":"Kumar","year":"2018","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.beha.2023.101466_bib40","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"issue":"5271","key":"10.1016\/j.beha.2023.101466_bib41","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1126\/science.273.5271.70","article-title":"The aging immune system: primer and prospectus","volume":"273","author":"Miller","year":"1996","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.beha.2023.101466_bib42","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.bbmt.2009.07.005","article-title":"Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization","volume":"15","author":"Richa","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.beha.2023.101466_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bbmt.2008.02.005","article-title":"Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates","volume":"14","author":"Nakamura","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101466_bib44","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1182\/blood-2022-162742","article-title":"Comparison of allogeneic hematopoietic cell transplantation outcomes from younger matched unrelated donor versus older sibling donor for acute myeloid leukemia","volume":"140","author":"Abid","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101466_bib45","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.bbmt.2015.08.009","article-title":"Suitability criteria for adult related donors: a consensus statement from the worldwide Network for blood and marrow transplantation standing committee on donor issues","volume":"21","author":"Worel","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1 Suppl","key":"10.1016\/j.beha.2023.101466_bib46","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.bbmt.2009.10.031","article-title":"Selection of adult unrelated hematopoietic stem cell donors: beyond HLA","volume":"16","author":"Confer","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.beha.2023.101466_bib47","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJM200101183440303","article-title":"Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers","volume":"344","author":"Bensinger","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101466_bib48","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2011.197","article-title":"Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4","volume":"26","author":"Rettig","year":"2012","journal-title":"Leukemia"},{"issue":"28","key":"10.1016\/j.beha.2023.101466_bib49","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1200\/JCO.2008.20.7209","volume":"27","author":"DiPersio","year":"2009","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.beha.2023.101466_bib50","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101466_bib51","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.bbmt.2018.01.039","article-title":"Plerixafor plus granulocyte colony-stimulating factor for patients with non-hodgkin lymphoma and multiple myeloma: long-term follow-up report","volume":"24","author":"Micallef","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1016\/j.beha.2023.101466_bib52","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1200\/JCO.2005.09.020","article-title":"Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials","volume":"23","author":"Group","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101466_bib53","series-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides","author":"Auletta","year":"2021"},{"issue":"3","key":"10.1016\/j.beha.2023.101466_bib54","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2023.101466_bib55","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood-2009-07-231068","article-title":"Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies","volume":"115","author":"Barker","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2023.101466_bib56","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1182\/blood-2004-07-2717","article-title":"Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy","volume":"105","author":"Barker","year":"2005","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2023.101466_bib57","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1405584","article-title":"One-unit versus two-unit cord-blood transplantation for hematologic cancers","volume":"371","author":"Wagner","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.beha.2023.101466_bib58","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/blood.2021011719","article-title":"Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2023.101466_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm.2080","article-title":"Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution","volume":"16","author":"Delaney","year":"2010","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.beha.2023.101466_bib60","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.bbmt.2017.05.002","article-title":"Ex vivo mesenchymal precursor cell-expanded cord blood transplantation after reduced-intensity conditioning regimens improves time to neutrophil recovery","volume":"23","author":"Mehta","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 2","key":"10.1016\/j.beha.2023.101466_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2022-171463","article-title":"Post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as the new standard for graft-versus-host disease (GVHD) prophylaxis in reduced intensity conditioning: results from phase III BMT CTN 1703","volume":"140","author":"Holtan","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2023.101466_bib62","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2023.101466_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100829","article-title":"AML and the art of remission maintenance","volume":"49","author":"de Lima","year":"2021","journal-title":"Blood Rev"},{"issue":"5","key":"10.1016\/j.beha.2023.101466_bib64","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"10.1016\/j.beha.2023.101466_bib65","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.beha.2023.101466_bib66","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2023.101466_bib67","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood-2022-169011","article-title":"Impact of allogeneic hematopoietic cell transplantation in first complete remission in addition to FLT3 inhibition with quizartinib in acute myeloid leukemia with FLT3-internal tandem duplication: results from the quantum-first trial","volume":"140","author":"Schlenk","year":"2022","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.beha.2023.101466_bib68","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1182\/blood.2021011583","article-title":"Follow-up of patients with R\/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial","volume":"139","author":"Perl","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101466_bib69","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1182\/blood-2019-124322","article-title":"BMT CTN protocol 1506: a phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-itd+ AML","volume":"134","author":"Levis","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2023.101466_bib70","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2023.101466_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.801632","article-title":"Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis","volume":"9","author":"Kungwankiattichai","year":"2022","journal-title":"Front Med"},{"issue":"22","key":"10.1016\/j.beha.2023.101466_bib72","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","article-title":"Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies","volume":"6","author":"Fathi","year":"2022","journal-title":"Blood Adv"},{"issue":"34","key":"10.1016\/j.beha.2023.101466_bib73","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:09:51Z","timestamp":1761498591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1521692623000270"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101466","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic hematopoietic cell transplantation in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101466"}}